# Addressing Barriers in Care Management, Shared Decision-making Alignment, and Educational Needs on Novel Immunotherapy Combinations in Melanoma

Tariqa Ackbarali, PhD¹; Megan Schollenberger, MSN, CRNP²; Omid Hamid, MD³; and Evan J. Lipson, MD² <sup>1</sup>PlatformQ Health Education; <sup>2</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; <sup>3</sup>The Angeles Clinic and Research Institute, Cedars-Sinai Cancer

This activity was supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
















# INTRODUCTION

Immunotherapy is being used increasingly to treat patients with locally-advanced unresectable or metastatic melanoma. To optimize patient care, members of the multidisciplinary healthcare team and their patients need up-to-date information about the latest therapies and the myraid of factors that can influence outcomes. To assess patient-clinician alignment on perceptions of care, an educational initiative was designed for clinicians and patients/caregivers.



# METHODOLOGY

## **Educational Program and Evaluation Details**



Advocacy groups: Melanoma Research Foundation (MRF) and Melanoma Action Coalition (MAC)

Education: PlatformQ Health Education and Partners for Advancing Clinical Education (PACE)



## Interventions

Patient education: 60-minute online-live and enduring activity (launched January 25, 2023), as well as targeted social-media videos via Facebook and Instagram

Title: Partnering with Your Team to Select Treatment for Newly Diagnosed Metastatic Melanoma

Clinician education: 60-minute online-live and enduring CME activity (launched February 13, 2023), as well as targeted micro-learning videos (4 posts) via LinkedIn

Title: Applying a Patient-centered Approach to Unresectable and Metastatic Melanoma

Patient education: Questions were asked during in-session polling, in the post-activity evaluation, and qualitative interviews were conducted to clarify patterns seen in survey data.

Clinician education: Questions were asked before and immediately post activity completion.



## **Data Collected**

Patient education: Engagement (platform views, social-media views); present knowledge and attitudes; perceived barriers; intended behavior changes; self-reported behavior change; one-on-one patient interviews

Clinician education: Engagement (CME participants, learners and completers, micro-learning completers); changes in knowledge and competence; present attitudes and practice behaviors; intended practice changes; self-reported practice changes


# **Faculty**



Co-Director, Cutaneous



Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University



Megan Schollenberger, MSN, CRNP

# RESULTS

**Engagement** 

Patient education:


456 platform views



views

melanoma patients

per month



# Female

## **Current Treatment Stage**

8%	40%	31%	46%
newly agnosed	watch-and-wait	recurrent or relapsed	in remission

## Clinician education:

participants

(38 live, 728

enduring,

**Specialty** 

2,213 micro-learning)

# 2,979

identified as treaters seeing an average of 8






Micro-learning breakdown:

1,082 dermatologists

# 37%



## Knowledge, Attitudes, Barriers

Patient reported challenges

Provider reported challenges

in treatment decision-making:

of patient learners

were confident

shared treatment


decision-making

treatmen

31%

54%

## Patient education:



38%

We all need to continue educating patients about that."

23%

31%

At baseline, patients are more confident than clinicians when engaging

Patient vs provider challenges in managing melanoma:

"very satisfied" with their current treatment

"It's best to be seen at an academic setting by a multidisciplinary team when

to go to a center until the melanoma returns. Thanks for stressing that point!

first diagnosed... unfortunately, so many community HCPs advocate for waiting

activities

Stage IV melanoma survivor and advocate

**15**%

23%

of clinician learners

were confident

are under the care of a

have anxiety

progression

anxiety about

treatment

efficacy

# **CME Baseline Snapshot**

Low baseline knowledge of reported efficacy data for immunotherapy combinations

**Low** baseline knowledge of

timing of immunotherapy

Low baseline competency

inhibitor combination

recommending a patient for a

clinical trial of a PD-1 and LAG3

survival benefit

**CME Learner Insights** 

Very likely to incorporate novel immunotherapy combinations

Moderate baseline awareness of adverse events associated with a PD-1 and LAG3 inhibitor combination

50%

60%

46%

infusion that increases patient





24%

# CONCLUSION

Patient and clinician assessments provided an opportunity to determine misalignments in perceptions of barriers and patient care experiences, as well as revealing educational needs for clinicians. As novel immunotherapy combinations continue to become available for patients with unresectable melanoma, it is important to increase awareness of clinical data and foster practical strategies to improve patient-centered care.

Author contact: tackbarali@platformq.com